ArticleMolecular therapy. Methods & clinical development2014
Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.
Open access · goldAbstract read
In one paragraph
Article in Molecular therapy. Methods & clinical development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Light microscopic and heterogeneity analysis of astrocytes in the common marmoset brain.Journal of neuroscience research · 2021Article
- Aging research using the common marmoset: Focus on aging interventions.Nutrition and healthy aging · 2019Article
- Expression and localization of CB1R, NAPE-PLD, and FAAH in the vervet monkey nucleus accumbens.Scientific reports · 2018Article
- Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.Human gene therapy methods · 2016Article
- Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business!Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Nathan VanderVeenDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Christopher ParanDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Ashley AppelhansDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Johnny KrasinkiewiczDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Rosemary LemonsDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Henry AppelmanDepartment of Pathology, The University of Michigan School of Medicine, University Hospital, Ann Arbor, Michigan, USA.
Robert DohertyDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Donna PalmerDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Philip NgDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Pedro R LowensteinDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Maria G CastroDepartment of Neurosurgery, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA ; Department of Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
University of Michigan–Ann Arbor · USBaylor College of Medicine · US
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MMichigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9MMICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MTRAINING IN CLINICAL AND BASIC NEUROSCIENCET32NS007222 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Henry L Paulson · 1985 to 2026
$8.0MTraining Program in Tumor MicroenvironmentT32CA009676 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, Analisa Virginia DiFeo · 1992 to 2026
$7.3MGutless Adenovirus Mediated Gene Therapy for GliomaU01NS052465 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2007 to 2011
$3.1MEngineering the Brain Immune System for Tumor TherapyR01NS057711 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2009 to 2013
$2.0MCrosstalk between glioma cells & immune cells in the tumor microenvironment: TherR01NS074387 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2011 to 2015
$1.9MBrain immune responses:Cellular & Molecular MechanismsR01NS061107 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2008 to 2012
$1.7MMechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7MGene Therapy and the Brain: Neuroimmune InteractionsR01NS054193 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2007 to 2011
$1.6MInhibiting glioma invasion using targeted nanoparticlesR21NS084275 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2014
$420kNCATS NIH HHS UL1 TR000433NCI NIH HHS P30 CA046592NCI NIH HHS T32 CA009676NIGMS NIH HHS T32 GM007863NINDS NIH HHS F32 NS058156NINDS NIH HHS R01 NS054193NINDS NIH HHS R01 NS057711NINDS NIH HHS R01 NS061107NINDS NIH HHS R01 NS074387NINDS NIH HHS R01 NS082311NINDS NIH HHS R21 NS084275NINDS NIH HHS T32 NS007222NINDS NIH HHS U01 NS052465
Abstract
We developed a combined conditional cytotoxic,
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.